Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

v3.23.1
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Oct. 06, 2021
Feb. 28, 2023
Aug. 31, 2022
Dec. 31, 2022
Mar. 31, 2023
Jan. 31, 2022
Agreements            
Long-term royalty and commercial payment receivables       $ 63,683 $ 73,333  
Contingent consideration under RPAs and CPPAs       75 125  
Affitech | Commercial Payment Purchase Agreement            
Agreements            
Upfront payment $ 6,000          
Maximum payments based on achievement of regulatory and sales milestones 20,000          
Long-term royalty and commercial payment receivables 14,000          
Maximum payable on regulatory milestone 8,000          
Maximum payable on sales milestone $ 12,000         $ 12,000
Cash receipts for achievement of contractual milestones   $ 2,400 $ 500      
Reduction in long-term royalty receivable balance due to receipt of payment   $ 2,400 $ 500      
Amount of allowance for credit losses       0 $ 0  
Affitech | Commercial Payment Purchase Agreement | United States            
Agreements            
Milestone payment       5,000    
Affitech | Commercial Payment Purchase Agreement | Europe            
Agreements            
Milestone payment       $ 3,000    
Affitech | Commercial Payment Purchase Agreement | Faricimab            
Agreements            
Payments eligible to receive (as a percent) 0.50%          
Commercial payment receivable term 10 years          
Affitech | Commercial Payment Purchase Agreement | Regulatory milestones            
Agreements            
Contingent consideration under RPAs and CPPAs $ 8,000